Efficacy of cabergoline in non-irradiated patients with acromegaly: a multi-centre cohort study
Authors' conclusion
In non-irradiated patients, cabergoline normalises IGF-1 in around one-third and achieves both IGF-1 and GH targets in approximately one out of ten cases. SRL+cabergoline is less efficient than previously reported possibly due to differences in studies methodology and impact of confounding factors.
Study context
- Population
- Patients with acromegaly and no previous pituitary radiotherapy, four UK pituitary centres (Birmingham, Bristol, Leicester, Oxford)
- Participants
- 69 vs 26
- Exposure
- Cabergoline monotherapy; Somatostatin receptor ligand (SRL) + cabergoline
- Cabergoline monotherapyn = 69
- SRL+cabergolinen = 26
- Outcome
- Normal IGF-1 (current biochemical criteria)
Methodological detailsmulticentre, four UK pituitary centres
- Multicentre
- Four UK pituitary centres
Main finding
As reported in the abstract
Normal IGF-1
- Cabergoline monotherapy (n=69): achieved normal IGF-1
- 31.9%
- Cabergoline monotherapy: normal IGF-1 in GH-secreting tumours
- 25%
- Cabergoline monotherapy: normal IGF-1 in GH+prolactin co-secreting tumours
- 60%
- SRL+cabergoline (n=26): achieved normal IGF-1
- 23.1%
- SRL+cabergoline: normal IGF-1 in GH-secreting tumours
- 15.8%
- SRL+cabergoline: normal IGF-1 in GH+prolactin co-secreting tumours
- 33.3%
Observational data: associations, not effects.
Further findings
Predictors of IGF-1 normalisation on cabergoline monotherapy
- GH+prolactin co-secreting adenoma (B 1.50, p=0.02)
- Lower pre-cabergoline IGF-1 xULN (B −0.70, p=0.02)
- Median weekly cabergoline dose similar between responders and non-responders
Normal IGF-1 and GH <1 mcg/L, and tumour shrinkage, on cabergoline monotherapy
- Both normal IGF-1 and GH <1 mcg/L
- 12.9%
- Tumour shrinkage in GH-secreting adenomas
- 29.4%
Normal IGF-1 and GH <1 mcg/L on SRL+cabergoline
- Normal IGF-1 and GH <1 mcg/L, SRL+cabergoline cohort
- 17.4%
Original publication
Efficacy of cabergoline in non-irradiated patients with acromegaly: a multi-centre cohort study. Eur J Endocrinol. Published 17 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →